speb/financial-data huggingface dataset:
PCRX cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: 5432000.00
PCRX income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 5432000.00
PCRX income_statement (quarterly, 2025-09-30) — Net Interest Income: 4255000.00
PCRX cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 47484000.00
PCRX cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -205236000.00
PCRX cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: -205236000.00
PCRX income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 4255000.00
PCRX cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -2211000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Net PPE: 191654000.00
PCRX cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -3870000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 324501000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Assets: 120188000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 4587000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 120188000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 4587000.00
PCRX income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 42142000.00
PCRX income_statement (quarterly, 2025-09-30) — Normalized Income: 11573460.00
PCRX cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 60834000.00
PCRX income_statement (quarterly, 2025-09-30) — Operating Income: 13153000.00
PCRX income_statement (quarterly, 2025-09-30) — Operating Revenue: 179516000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 42965902.00
PCRX balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 43469000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: 4123000.00
PCRX income_statement (quarterly, 2025-09-30) — Other Gand A: 23180000.00
PCRX income_statement (quarterly, 2025-09-30) — Other Income Expense: -7884000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 382396000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Other Investments: 20271000.00
PCRX cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 1307000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 43138000.00
PCRX income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: -110000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Other Properties: 44266000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 98745000.00
PCRX income_statement (quarterly, 2025-09-30) — Other Special Charges: -22165000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Payables: 17687000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 97330000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Preferred Stock: 0.00
PCRX income_statement (quarterly, 2025-09-30) — Pretax Income: 9524000.00
PCRX cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 12000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Properties: 0.00
PCRX cash_flow (quarterly, 2025-09-30) — Purchase Of Business: 0.00
PCRX cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: -38765000.00
PCRX cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -3870000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Raw Materials: 46428000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Receivables: 115268000.00
PCRX income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 27409000.00
PCRX income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 21191000.00
PCRX cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -306236000.00
PCRX cash_flow (quarterly, 2025-09-30) — Repurchase Of Capital Stock: -50041000.00
PCRX income_statement (quarterly, 2025-09-30) — Research And Development: 25966000.00
PCRX income_statement (quarterly, 2025-09-30) — Restructuring And Mergern Acquisition: 4073000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -200959000.00
PCRX income_statement (quarterly, 2025-09-30) — Salaries And Wages: 10146000.00
PCRX cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 86249000.00
PCRX income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 58471000.00
PCRX income_statement (quarterly, 2025-09-30) — Selling General And Administration: 91797000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Share Issued: 47735248.00
PCRX income_statement (quarterly, 2025-09-30) — Special Income Charges: -7774000.00
PCRX cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 13978000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 727214000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 324501000.00
PCRX income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: -1632540.00
PCRX income_statement (quarterly, 2025-09-30) — Tax Provision: 4092000.00
PCRX income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.21
PCRX balance_sheet (quarterly, 2025-09-30) — Total Assets: 1297577000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 1103935000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Total Debt: 425308000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 727214000.00
PCRX income_statement (quarterly, 2025-09-30) — Total Expenses: 166363000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 570363000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 734826000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 463285000.00
PCRX income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: 6362000.00
PCRX income_statement (quarterly, 2025-09-30) — Total Other Finance Cost: 626000.00
PCRX income_statement (quarterly, 2025-09-30) — Total Unusual Items: -7774000.00
PCRX income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: -7774000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Treasury Shares Number: 4769346.00
PCRX balance_sheet (quarterly, 2025-09-30) — Treasury Stock: 125543000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Work In Process: 18840000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Working Capital: 455673000.00
PCRX income_statement (annual, 2025-12-31) — +Operating Expense: 557471000.00
PCRX income_statement (quarterly, 2025-12-31) — +Operating Expense: 167495000.00
PCRX income_statement (annual, 2025-12-31) — +Total Revenue: 726411000.00
PCRX income_statement (quarterly, 2025-12-31) — +Total Revenue: 196873000.00
PCRX balance_sheet (annual, 2025-12-31) — Accounts Payable: 15150000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 15150000.00
PCRX balance_sheet (annual, 2025-12-31) — Accounts Receivable: 124069000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 124069000.00
PCRX balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -137703000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -137703000.00
PCRX balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 1064623000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 1064623000.00
PCRX income_statement (annual, 2025-12-31) — Amortization: 57288000.00
PCRX income_statement (quarterly, 2025-12-31) — Amortization: 14322000.00
PCRX income_statement (annual, 2025-12-31) — Amortization Of Intangibles Income Statement: 57288000.00
PCRX income_statement (quarterly, 2025-12-31) — Amortization Of Intangibles Income Statement: 14322000.00
PCRX cash_flow (annual, 2025-12-31) — Asset Impairment Charge: 36866000.00
PCRX cash_flow (quarterly, 2025-12-31) — Asset Impairment Charge: 0.00
PCRX income_statement (annual, 2025-12-31) — Average Dilution Earnings: 0.00
PCRX income_statement (annual, 2025-12-31) — Basic Average Shares: 44566000.00
PCRX income_statement (quarterly, 2025-12-31) — Basic Average Shares: 42491000.00
PCRX income_statement (annual, 2025-12-31) — Basic EPS: 0.16
PCRX income_statement (quarterly, 2025-12-31) — Basic EPS: 0.04
PCRX cash_flow (annual, 2025-12-31) — Beginning Cash Position: 276774000.00
PCRX cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 147589000.00
PCRX cash_flow (annual, 2025-12-31) — Capital Expenditure: -15333000.00
PCRX cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -218000.00
PCRX balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 46015000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 46015000.00
PCRX balance_sheet (annual, 2025-12-31) — Capital Stock: 48000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Capital Stock: 48000.00
PCRX balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 158545000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 158545000.00
PCRX balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 238424000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 238424000.00
PCRX cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: -369627000.00
PCRX cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: -51652000.00
PCRX cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: 99481000.00
PCRX cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: 19333000.00
PCRX cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: 151994000.00
PCRX cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 43689000.00
PCRX cash_flow (annual, 2025-12-31) — Change In Account Payable: -5598000.00
PCRX cash_flow (quarterly, 2025-12-31) — Change In Account Payable: -2929000.00
PCRX cash_flow (annual, 2025-12-31) — Change In Accrued Expense: 6853000.00
PCRX cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: 13998000.00
PCRX cash_flow (annual, 2025-12-31) — Change In Inventory: -27567000.00
PCRX cash_flow (quarterly, 2025-12-31) — Change In Inventory: 4817000.00
PCRX cash_flow (annual, 2025-12-31) — Change In Payable: -5598000.00
PCRX cash_flow (quarterly, 2025-12-31) — Change In Payable: -2929000.00
PCRX cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 1255000.00
PCRX cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 11069000.00
PCRX cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: -1212000.00
PCRX cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: 12699000.00
PCRX cash_flow (annual, 2025-12-31) — Change In Receivables: -10742000.00
PCRX cash_flow (quarterly, 2025-12-31) — Change In Receivables: -8799000.00
PCRX cash_flow (annual, 2025-12-31) — Change In Working Capital: -38266000.00
PCRX cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 14707000.00
PCRX cash_flow (annual, 2025-12-31) — Changes In Account Receivables: -10742000.00
PCRX cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: -8799000.00
PCRX cash_flow (annual, 2025-12-31) — Changes In Cash: -118152000.00
PCRX cash_flow (quarterly, 2025-12-31) — Changes In Cash: 11370000.00
PCRX balance_sheet (annual, 2025-12-31) — Common Stock: 48000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Common Stock: 48000.00
PCRX balance_sheet (annual, 2025-12-31) — Common Stock Equity: 693111000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 693111000.00
PCRX cash_flow (annual, 2025-12-31) — Common Stock Payments: -148328000.00
PCRX cash_flow (quarterly, 2025-12-31) — Common Stock Payments: -48248000.00
PCRX balance_sheet (annual, 2025-12-31) — Construction In Progress: 9485000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 9485000.00
PCRX income_statement (annual, 2025-12-31) — Cost Of Revenue: 149749000.00
PCRX income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 40299000.00
PCRX balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 57760000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 57760000.00
PCRX balance_sheet (annual, 2025-12-31) — Current Assets: 547974000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Current Assets: 547974000.00
PCRX balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 9839000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 9839000.00
PCRX balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 9839000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 9839000.00
PCRX balance_sheet (annual, 2025-12-31) — Current Liabilities: 120590000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 120590000.00
PCRX cash_flow (annual, 2025-12-31) — Deferred Income Tax: 6477000.00
PCRX cash_flow (quarterly, 2025-12-31) — Deferred Income Tax: -3744000.00
PCRX cash_flow (annual, 2025-12-31) — Deferred Tax: 6477000.00
PCRX cash_flow (quarterly, 2025-12-31) — Deferred Tax: -3744000.00
PCRX cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 91023000.00
PCRX cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 21342000.00
PCRX income_statement (annual, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 57288000.00
PCRX income_statement (quarterly, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 14322000.00
PCRX cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 91023000.00
PCRX cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 21342000.00
PCRX income_statement (annual, 2025-12-31) — Depreciation And Amortization In Income Statement: 57288000.00
PCRX income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 14322000.00
PCRX income_statement (annual, 2025-12-31) — Diluted Average Shares: 45042000.00
PCRX income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 42981000.00
PCRX income_statement (annual, 2025-12-31) — Diluted EPS: 0.16
PCRX income_statement (quarterly, 2025-12-31) — Diluted EPS: 0.04
PCRX income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: 7034000.00
PCRX income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 1637000.00
PCRX income_statement (annual, 2025-12-31) — EBIT: 31480000.00
PCRX income_statement (quarterly, 2025-12-31) — EBIT: 3943000.00
PCRX income_statement (annual, 2025-12-31) — EBITDA: 122503000.00
PCRX income_statement (quarterly, 2025-12-31) — EBITDA: 25285000.00
PCRX cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: -77000.00
PCRX cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: -414000.00
PCRX cash_flow (annual, 2025-12-31) — End Cash Position: 158545000.00
PCRX cash_flow (quarterly, 2025-12-31) — End Cash Position: 158545000.00
PCRX cash_flow (annual, 2025-12-31) — Financing Cash Flow: -369627000.00
PCRX cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: -51652000.00
PCRX balance_sheet (annual, 2025-12-31) — Finished Goods: 81327000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Finished Goods: 81327000.00
PCRX cash_flow (annual, 2025-12-31) — Free Cash Flow: 136661000.00
PCRX cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 43471000.00
PCRX balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 4327000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 4327000.00
PCRX income_statement (annual, 2025-12-31) — General And Administrative Expense: 142143000.00
PCRX income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 39998000.00
PCRX balance_sheet (annual, 2025-12-31) — Goodwill: 20214000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Goodwill: 20214000.00
PCRX balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 388314000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 388314000.00
PCRX balance_sheet (annual, 2025-12-31) — Gross PPE: 320170000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Gross PPE: 320170000.00
PCRX income_statement (annual, 2025-12-31) — Gross Profit: 576662000.00
PCRX income_statement (quarterly, 2025-12-31) — Gross Profit: 156574000.00
PCRX income_statement (annual, 2025-12-31) — Impairment Of Capital Assets: 0.00
PCRX income_statement (quarterly, 2025-12-31) — Impairment Of Capital Assets: -25866000.00
PCRX income_statement (annual, 2025-12-31) — Interest Expense: 14606000.00
PCRX income_statement (quarterly, 2025-12-31) — Interest Expense: 3372000.00
PCRX income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 14606000.00
PCRX income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 3372000.00
PCRX income_statement (annual, 2025-12-31) — Interest Income: 22732000.00
PCRX income_statement (quarterly, 2025-12-31) — Interest Income: 2295000.00
PCRX income_statement (annual, 2025-12-31) — Interest Income Non Operating: 22732000.00
PCRX income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 2295000.00
PCRX cash_flow (annual, 2025-12-31) — Interest Paid Supplemental Data: 15235000.00
PCRX cash_flow (quarterly, 2025-12-31) — Interest Paid Supplemental Data: 4845000.00
PCRX balance_sheet (annual, 2025-12-31) — Interest Payable: 782000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Interest Payable: 782000.00
PCRX balance_sheet (annual, 2025-12-31) — Inventory: 152863000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Inventory: 152863000.00
PCRX balance_sheet (annual, 2025-12-31) — Invested Capital: 1065300000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Invested Capital: 1065300000.00
PCRX cash_flow (annual, 2025-12-31) — Investing Cash Flow: 99481000.00
PCRX cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: 19333000.00
PCRX cash_flow (annual, 2025-12-31) — Issuance Of Debt: 101000000.00
PCRX cash_flow (quarterly, 2025-12-31) — Issuance Of Debt: 0.00
PCRX balance_sheet (annual, 2025-12-31) — Leases: 77450000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Leases: 77450000.00
PCRX balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 36176000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 36176000.00
PCRX balance_sheet (annual, 2025-12-31) — Long Term Debt: 372189000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 372189000.00
PCRX balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 408365000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 408365000.00
PCRX cash_flow (annual, 2025-12-31) — Long Term Debt Issuance: 101000000.00
PCRX cash_flow (quarterly, 2025-12-31) — Long Term Debt Issuance: 0.00
PCRX cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -317799000.00
PCRX cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: -5000000.00
PCRX balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 191458000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 191458000.00
PCRX cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: -16702000.00
PCRX cash_flow (quarterly, 2025-12-31) — Net Business Purchase And Sale: 0.00
PCRX cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: -148328000.00
PCRX cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: -48248000.00
PCRX balance_sheet (annual, 2025-12-31) — Net Debt: 213644000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Net Debt: 213644000.00
PCRX income_statement (annual, 2025-12-31) — Net Income: 7034000.00
PCRX income_statement (quarterly, 2025-12-31) — Net Income: 1637000.00
PCRX income_statement (annual, 2025-12-31) — Net Income Common Stockholders: 7034000.00
PCRX income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 1637000.00
PCRX income_statement (annual, 2025-12-31) — Net Income Continuous Operations: 7034000.00
PCRX income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 1637000.00
PCRX income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 7034000.00
PCRX income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 1637000.00
PCRX income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 7034000.00
PCRX income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 1637000.00
PCRX cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: 7034000.00
PCRX cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: 1637000.00
PCRX income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: 7034000.00
PCRX income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 1637000.00
PCRX income_statement (annual, 2025-12-31) — Net Interest Income: 5286000.00
PCRX income_statement (quarterly, 2025-12-31) — Net Interest Income: -1597000.00
PCRX cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: 131516000.00
PCRX cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: 19551000.00
PCRX cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -216799000.00
PCRX cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: -5000000.00
PCRX cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -216799000.00
PCRX cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: -5000000.00
PCRX income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 5286000.00
PCRX income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -1597000.00
PCRX cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -7803000.00
PCRX cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: -126000.00
PCRX balance_sheet (annual, 2025-12-31) — Net PPE: 182467000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Net PPE: 182467000.00
PCRX cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -15333000.00
PCRX cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -218000.00
PCRX balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 304797000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 304797000.00
PCRX balance_sheet (annual, 2025-12-31) — Non Current Deferred Assets: 123854000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Assets: 123854000.00
PCRX balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 4213000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 4213000.00
PCRX balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 123854000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 123854000.00
PCRX balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 4213000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 4213000.00
PCRX income_statement (annual, 2025-12-31) — Normalized EBITDA: 123486000.00
PCRX income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 12024000.00
PCRX income_statement (annual, 2025-12-31) — Normalized Income: 7810570.00
PCRX income_statement (quarterly, 2025-12-31) — Normalized Income: -8839190.00
PCRX cash_flow (annual, 2025-12-31) — Operating Cash Flow: 151994000.00
PCRX cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 43689000.00
PCRX cash_flow (annual, 2025-12-31) — Operating Gains Losses: 983000.00
PCRX cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: 0.00
PCRX income_statement (annual, 2025-12-31) — Operating Income: 19191000.00
PCRX income_statement (quarterly, 2025-12-31) — Operating Income: -10921000.00
PCRX income_statement (annual, 2025-12-31) — Operating Revenue: 726411000.00
PCRX income_statement (quarterly, 2025-12-31) — Operating Revenue: 196873000.00
PCRX balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 41116739.00
PCRX balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 41116739.00
PCRX balance_sheet (annual, 2025-12-31) — Other Current Assets: 32618000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 32618000.00
PCRX balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: 4327000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: 4327000.00
PCRX income_statement (annual, 2025-12-31) — Other Gand A: 100277000.00
PCRX income_statement (quarterly, 2025-12-31) — Other Gand A: 30257000.00
PCRX income_statement (annual, 2025-12-31) — Other Income Expense: -7603000.00
PCRX income_statement (quarterly, 2025-12-31) — Other Income Expense: 13089000.00
PCRX balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 368100000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 368100000.00
PCRX cash_flow (annual, 2025-12-31) — Other Non Cash Items: -9625000.00
PCRX cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: -3752000.00
PCRX balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 22308000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 22308000.00
PCRX balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 38638000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 38638000.00
PCRX income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: -6620000.00
PCRX income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: -172000.00
PCRX income_statement (annual, 2025-12-31) — Other Operating Expenses: 14112000.00
PCRX balance_sheet (annual, 2025-12-31) — Other Properties: 41777000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Other Properties: 41777000.00
PCRX balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 79879000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 79879000.00
PCRX income_statement (annual, 2025-12-31) — Other Special Charges: 983000.00
PCRX income_statement (quarterly, 2025-12-31) — Other Special Charges: 16148000.00
PCRX balance_sheet (annual, 2025-12-31) — Payables: 15150000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Payables: 15150000.00
PCRX balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 72910000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 72910000.00
PCRX balance_sheet (annual, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 37841000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 37841000.00
PCRX balance_sheet (annual, 2025-12-31) — Preferred Stock: 0.00
PCRX balance_sheet (quarterly, 2025-12-31) — Preferred Stock: 0.00
PCRX income_statement (annual, 2025-12-31) — Pretax Income: 16874000.00
PCRX income_statement (quarterly, 2025-12-31) — Pretax Income: 571000.00
PCRX cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 3303000.00
PCRX cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 1722000.00
PCRX balance_sheet (annual, 2025-12-31) — Properties: 0.00
PCRX balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
PCRX cash_flow (annual, 2025-12-31) — Purchase Of Business: -16702000.00
PCRX cash_flow (quarterly, 2025-12-31) — Purchase Of Business: 0.00
PCRX cash_flow (annual, 2025-12-31) — Purchase Of Investment: -142291000.00
PCRX cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: -27591000.00
PCRX cash_flow (annual, 2025-12-31) — Purchase Of PPE: -15333000.00
PCRX cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -218000.00
PCRX balance_sheet (annual, 2025-12-31) — Raw Materials: 43335000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Raw Materials: 43335000.00
PCRX balance_sheet (annual, 2025-12-31) — Receivables: 124069000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Receivables: 124069000.00
PCRX income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 116014000.00
PCRX income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 33279000.00
PCRX income_statement (annual, 2025-12-31) — Reconciled Depreciation: 91023000.00
PCRX income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 21342000.00
PCRX cash_flow (annual, 2025-12-31) — Repayment Of Debt: -317799000.00
PCRX cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -5000000.00
PCRX cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: -148328000.00
PCRX cash_flow (quarterly, 2025-12-31) — Repurchase Of Capital Stock: -48248000.00
PCRX income_statement (annual, 2025-12-31) — Research And Development: 117312000.00
PCRX income_statement (quarterly, 2025-12-31) — Research And Development: 37453000.00
PCRX income_statement (annual, 2025-12-31) — Restructuring And Mergern Acquisition: 14112000.00
PCRX income_statement (quarterly, 2025-12-31) — Restructuring And Mergern Acquisition: 10569000.00
PCRX balance_sheet (annual, 2025-12-31) — Retained Earnings: -199322000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -199322000.00
PCRX income_statement (annual, 2025-12-31) — Salaries And Wages: 41866000.00
PCRX income_statement (quarterly, 2025-12-31) — Salaries And Wages: 9741000.00
PCRX cash_flow (annual, 2025-12-31) — Sale Of Investment: 273807000.00
PCRX cash_flow (quarterly, 2025-12-31) — Sale Of Investment: 47142000.00
PCRX income_statement (annual, 2025-12-31) — Selling And Marketing Expense: 226616000.00
PCRX income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 61610000.00
PCRX income_statement (annual, 2025-12-31) — Selling General And Administration: 368759000.00
PCRX income_statement (quarterly, 2025-12-31) — Selling General And Administration: 101608000.00
PCRX balance_sheet (annual, 2025-12-31) — Share Issued: 47890777.00
PCRX balance_sheet (quarterly, 2025-12-31) — Share Issued: 47890777.00
PCRX income_statement (annual, 2025-12-31) — Special Income Charges: -983000.00
PCRX income_statement (quarterly, 2025-12-31) — Special Income Charges: 13261000.00
PCRX cash_flow (annual, 2025-12-31) — Stock Based Compensation: 57502000.00
PCRX cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 13499000.00
PCRX balance_sheet (annual, 2025-12-31) — Stockholders Equity: 693111000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 693111000.00
PCRX balance_sheet (annual, 2025-12-31) — Tangible Book Value: 304797000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 304797000.00
PCRX income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -206430.00
PCRX income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 2784810.00
PCRX income_statement (annual, 2025-12-31) — Tax Provision: 9840000.00
PCRX income_statement (quarterly, 2025-12-31) — Tax Provision: -1066000.00
PCRX income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.21
PCRX income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.21
PCRX balance_sheet (annual, 2025-12-31) — Total Assets: 1264917000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Total Assets: 1264917000.00
PCRX balance_sheet (annual, 2025-12-31) — Total Capitalization: 1065300000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 1065300000.00
PCRX balance_sheet (annual, 2025-12-31) — Total Debt: 418204000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Total Debt: 418204000.00
PCRX balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 693111000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 693111000.00
PCRX income_statement (annual, 2025-12-31) — Total Expenses: 707220000.00
PCRX income_statement (quarterly, 2025-12-31) — Total Expenses: 207794000.00
PCRX balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 571806000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 571806000.00
PCRX balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 716943000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 716943000.00
PCRX balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 451216000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 451216000.00
PCRX income_statement (annual, 2025-12-31) — Total Operating Income As Reported: 19191000.00
PCRX income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: 2340000.00
PCRX income_statement (annual, 2025-12-31) — Total Other Finance Cost: 2840000.00
PCRX income_statement (quarterly, 2025-12-31) — Total Other Finance Cost: 520000.00
PCRX income_statement (annual, 2025-12-31) — Total Unusual Items: -983000.00
PCRX income_statement (quarterly, 2025-12-31) — Total Unusual Items: 13261000.00
PCRX income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -983000.00
PCRX income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 13261000.00
PCRX balance_sheet (annual, 2025-12-31) — Treasury Shares Number: 6774038.00
PCRX balance_sheet (quarterly, 2025-12-31) — Treasury Shares Number: 6774038.00
PCRX balance_sheet (annual, 2025-12-31) — Treasury Stock: 176565000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Treasury Stock: 176565000.00
PCRX balance_sheet (annual, 2025-12-31) — Work In Process: 28201000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Work In Process: 28201000.00
PCRX balance_sheet (annual, 2025-12-31) — Working Capital: 427384000.00
PCRX balance_sheet (quarterly, 2025-12-31) — Working Capital: 427384000.00
PCRX income_statement (quarterly, 2026-03-31) — +Operating Expense: 136338000.00
PCRX income_statement (quarterly, 2026-03-31) — +Total Revenue: 177376000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 14012000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 125635000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -144710000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 1073809000.00
PCRX income_statement (quarterly, 2026-03-31) — Amortization: 14322000.00
PCRX income_statement (quarterly, 2026-03-31) — Amortization Of Intangibles Income Statement: 14322000.00
PCRX income_statement (quarterly, 2026-03-31) — Basic Average Shares: 40461000.00
PCRX income_statement (quarterly, 2026-03-31) — Basic EPS: 0.07
PCRX cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 158545000.00
PCRX cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -2724000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 43523000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Capital Stock: 48000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 144306000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 202180000.00
PCRX cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: -59398000.00
PCRX cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: 19441000.00
PCRX cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: 25680000.00
PCRX cash_flow (quarterly, 2026-03-31) — Change In Account Payable: -936000.00
PCRX cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: -10305000.00
PCRX cash_flow (quarterly, 2026-03-31) — Change In Inventory: 2491000.00
PCRX cash_flow (quarterly, 2026-03-31) — Change In Other Current Liabilities: 3288000.00
PCRX cash_flow (quarterly, 2026-03-31) — Change In Payable: -936000.00
PCRX cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -11241000.00
PCRX cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -4537000.00
PCRX cash_flow (quarterly, 2026-03-31) — Change In Receivables: -1567000.00
PCRX cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -11566000.00
PCRX cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: -1567000.00
PCRX cash_flow (quarterly, 2026-03-31) — Changes In Cash: -14277000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Common Stock: 48000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 653893000.00
PCRX cash_flow (quarterly, 2026-03-31) — Common Stock Payments: -50045000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 10951000.00
PCRX income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 36413000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 84957000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Current Assets: 514961000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 9818000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 9818000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 108787000.00
PCRX cash_flow (quarterly, 2026-03-31) — Deferred Income Tax: 1730000.00
PCRX cash_flow (quarterly, 2026-03-31) — Deferred Tax: 1730000.00
PCRX cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 21331000.00
PCRX income_statement (quarterly, 2026-03-31) — Depreciation Amortization Depletion Income Statement: 14322000.00
PCRX cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 21331000.00
PCRX income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 14322000.00
PCRX income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 40910000.00
PCRX income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.07
PCRX income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 2916000.00
PCRX income_statement (quarterly, 2026-03-31) — EBIT: 8176000.00
PCRX income_statement (quarterly, 2026-03-31) — EBITDA: 29507000.00
PCRX cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: 38000.00
PCRX cash_flow (quarterly, 2026-03-31) — End Cash Position: 144306000.00
PCRX cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: -59398000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Finished Goods: 70677000.00
PCRX cash_flow (quarterly, 2026-03-31) — Free Cash Flow: 22956000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: 3455000.00
PCRX income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 35778000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Goodwill: 19773000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 373000000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Gross PPE: 320400000.00
PCRX income_statement (quarterly, 2026-03-31) — Gross Profit: 140963000.00
PCRX cash_flow (quarterly, 2026-03-31) — Income Tax Paid Supplemental Data: 50000.00
PCRX income_statement (quarterly, 2026-03-31) — Interest Expense: 3178000.00
PCRX income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 3178000.00
PCRX income_statement (quarterly, 2026-03-31) — Interest Income: 1930000.00
PCRX income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 1930000.00
PCRX cash_flow (quarterly, 2026-03-31) — Interest Paid Supplemental Data: 1595000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Inventory: 150370000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Invested Capital: 1021549000.00
PCRX cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: 19441000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Leases: 77644000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 33705000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 367656000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 401361000.00
PCRX cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -5000000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 192396000.00
PCRX cash_flow (quarterly, 2026-03-31) — Net Business Purchase And Sale: -335000.00
PCRX cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: -50045000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Net Debt: 223350000.00
PCRX income_statement (quarterly, 2026-03-31) — Net Income: 2916000.00
PCRX income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 2916000.00
PCRX income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 2916000.00
PCRX income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 2916000.00
PCRX income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 2916000.00
PCRX cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: 2916000.00
PCRX income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 2916000.00
PCRX income_statement (quarterly, 2026-03-31) — Net Interest Income: -1769000.00
PCRX cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: 22500000.00
PCRX cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: -5000000.00
PCRX cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: -5000000.00
PCRX income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -1769000.00
PCRX cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -4355000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Net PPE: 175690000.00
PCRX cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -2724000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 280893000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Assets: 122115000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 4093000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 122115000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 4093000.00
PCRX income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 27230000.00
PCRX income_statement (quarterly, 2026-03-31) — Normalized Income: 1549800.00
PCRX cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: 25680000.00
PCRX income_statement (quarterly, 2026-03-31) — Operating Income: 4625000.00
PCRX income_statement (quarterly, 2026-03-31) — Operating Revenue: 177376000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 39309610.00
PCRX balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 36776000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: 3455000.00
PCRX income_statement (quarterly, 2026-03-31) — Other Gand A: 25712000.00
PCRX income_statement (quarterly, 2026-03-31) — Other Income Expense: 2142000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 353227000.00
PCRX cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: -2270000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 22768000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 40400000.00
PCRX income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: -135000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Other Properties: 39409000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 57874000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Payables: 14012000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 98969000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Preferred Stock: 0.00
PCRX income_statement (quarterly, 2026-03-31) — Pretax Income: 4998000.00
PCRX cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 2000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
PCRX cash_flow (quarterly, 2026-03-31) — Purchase Of Business: -335000.00
PCRX cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: 0.00
PCRX cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -2724000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Raw Materials: 39814000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Receivables: 125635000.00
PCRX income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 29404000.00
PCRX income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 21331000.00
PCRX cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -5000000.00
PCRX cash_flow (quarterly, 2026-03-31) — Repurchase Of Capital Stock: -50045000.00
PCRX income_statement (quarterly, 2026-03-31) — Research And Development: 28072000.00
PCRX income_statement (quarterly, 2026-03-31) — Restructuring And Mergern Acquisition: -2277000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -196406000.00
PCRX income_statement (quarterly, 2026-03-31) — Salaries And Wages: 10066000.00
PCRX cash_flow (quarterly, 2026-03-31) — Sale Of Investment: 22500000.00
PCRX income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 58166000.00
PCRX income_statement (quarterly, 2026-03-31) — Selling General And Administration: 93944000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Share Issued: 48328201.00
PCRX income_statement (quarterly, 2026-03-31) — Special Income Charges: 2277000.00
PCRX cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 13539000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 653893000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 280893000.00
PCRX income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 910800.00
PCRX income_statement (quarterly, 2026-03-31) — Tax Provision: 2082000.00
PCRX income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
PCRX balance_sheet (quarterly, 2026-03-31) — Total Assets: 1208534000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 1021549000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Total Debt: 411179000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 653893000.00
PCRX income_statement (quarterly, 2026-03-31) — Total Expenses: 172751000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 554641000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 693573000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 445854000.00
PCRX income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: 6902000.00
PCRX income_statement (quarterly, 2026-03-31) — Total Other Finance Cost: 521000.00
PCRX income_statement (quarterly, 2026-03-31) — Total Unusual Items: 2277000.00
PCRX income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 2277000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 9018591.00
PCRX balance_sheet (quarterly, 2026-03-31) — Treasury Stock: 227013000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Work In Process: 39879000.00
PCRX balance_sheet (quarterly, 2026-03-31) — Working Capital: 406174000.00
PCRX.V balance_sheet (annual, 2021-12-31) — Current Deferred Assets: 20500.00
PCRX.V income_statement (annual, 2022-12-31) — +Operating Expense: 563177.00
PCRX.V income_statement (annual, 2022-12-31) — +Total Revenue: 0.00
PCRX.V balance_sheet (annual, 2022-12-31) — Accounts Payable: 16465.00
PCRX.V balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 516632.00
PCRX.V income_statement (annual, 2022-12-31) — Basic Average Shares: 32547945.00
PCRX.V income_statement (annual, 2022-12-31) — Basic EPS: -0.02
PCRX.V cash_flow (annual, 2022-12-31) — Beginning Cash Position: 980025.00
PCRX.V balance_sheet (annual, 2022-12-31) — Capital Stock: 2743185.00
PCRX.V balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 2733379.00
PCRX.V balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 2733379.00
PCRX.V cash_flow (annual, 2022-12-31) — Cash Dividends Paid: 0.00
PCRX.V cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 1873537.00
PCRX.V cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -120183.00
PCRX.V cash_flow (annual, 2022-12-31) — Change In Other Working Capital: 20500.00
PCRX.V cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: -9878.00
PCRX.V cash_flow (annual, 2022-12-31) — Change In Working Capital: 10622.00
PCRX.V cash_flow (annual, 2022-12-31) — Changes In Cash: 1753354.00
PCRX.V balance_sheet (annual, 2022-12-31) — Common Stock: 2743185.00
PCRX.V balance_sheet (annual, 2022-12-31) — Common Stock Equity: 2716914.00